Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;51(4):319-333.
doi: 10.1016/j.idnow.2021.02.007. Epub 2021 Feb 27.

COVID-19 vaccines: Frequently asked questions and updated answers

M Lefebvre  1 , N Vignier  2 , B Pitard  3 , E Botelho-Nevers  4 , B Wyplosz  5 , R Cohen  6 , O Epaulard  7 ; SPILF Vaccination Prevention group
Affiliations
Review

COVID-19 vaccines: Frequently asked questions and updated answers

M Lefebvre et al. Infect Dis Now. 2021 Jun.

Abstract

At the end of December 2019, China notified the World Health Organization about a viral pneumonia epidemic soon to be named COVID-19, of which the infectious agent, SARS-CoV-2, was rapidly identified. Less than one year later, published phase 3 clinical trials underlined the effectiveness of vaccines utilizing hitherto unusual technology consisting in injection of the messenger RNA (m-RNA) of a viral protein. In the meantime, numerous clinical trials had failed to identify a maximally effective antiviral treatment, and mass vaccination came to be considered as the strategy most likely to put an end to the pandemic. The objective of this text is to address and hopefully answer the questions being put forward by healthcare professionals on the different anti-SARS-CoV-2 vaccines as regards their development, their modes of action, their effectiveness, their limits, and their utilization in different situations; we are proposing a report on both today's state of knowledge, and the 14 February 2021 recommendations of the French health authorities.

Keywords: COVID-19; Review; SARS-CoV-2; Vaccine.

PubMed Disclaimer

References

    1. Jiang S., Hillyer C., Du L. Neutralizing antibodies against SARS-CoV-2 and other human Coronaviruses. Trends Immunol. 2020;41:355–359. - PMC - PubMed
    1. Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other Coronavirus strains. Infect Dis Ther. 2020;9:1–20. - PMC - PubMed
    1. Van Riel D., de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19:810–812. - PubMed
    1. Trovato M., Sartorius R., D’Apice L., Manco R., De Berardinis P. Viral emerging diseases: challenges in developing vaccination strategies. Front Immunol. 2020;11:2130. - PMC - PubMed
    1. World Health Organization . 2021. Draft landscape and tracker of COVID-19 candidate vaccines. [Internet. Cited 2021 February 06. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand...]

Substances